Abstract

At present, in the medical field, drug screening is usually performed using in vivo drug experiments. However, it is very time-consuming and laborious to conduct in vivo experiments on a large number of drugs to be screened one by one. This paper attempts to propose using machine learning algorithms to perform preliminary screening of a large number of compounds to be screened and their molecular structures to reduce the workload of in vivo experiments. Among them, it is internationally recognized that there is an important association between breast cancer progression and the alpha subtype of the estrogen receptor. Anti-breast cancer drug candidates with excellent efficacy need to contain compounds that can better antagonize ERα activity. In this paper, the research object is narrowed down from compounds to the molecular structure of the compounds, and then the random forest regression algorithm is used to develop the molecular structure-ERα activity prediction model. Molecular structures with significant effects on biological activity were screened from molecular structure descriptors in numerous compounds. Four different kernel functions were used to conduct comparative experiments, and finally a support vector regression algorithm based on radial basis kernel function was established, which realized the quantitative prediction of compounds on biological activity of ERα, and could find potential compounds beneficial to breast cancer treatment. This is a novel, computer-based method for preliminary drug screening, which can help medical researchers effectively narrow the scope of experiments and achieve more accurate optimization of drugs.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call